Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FEMALAC
- Development stage
- Unknown
- Lead developer
- APOGEPHA Arzneimittel
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
FEMALAC is a medical product (medical device) developed by Apogepha for the prevention and supportive treatment of recurrent urinary tract infections (UTIs) and bladder infections (cystitis) caused by *E. coli*. The formulation consists of 2g of D-mannose combined with two probiotic strains, *Lactobacillus rhamnosus* and *Lactobacillus reuteri*. D-mannose functions by binding to the fimbriae of *E. coli* bacteria, preventing their attachment to the urinary tract lining and facilitating their removal via urination. The lactobacilli help to stabilize the vaginal and urinary microbiome and maintain an acidic pH, creating an environment less conducive to pathogen growth. It is provided as a drinking powder for oral administration.
- Brand names
- FEMALACFEMALAC Bacteria Blocker
- Other names
- Femalac-Apogepha
02
Targets
FimH (Type 1 fimbrial adhesin)
Beyond the preview
Go deeper on FEMALAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FEMALAC.